Overview

FOLFOXIRI With or Without Intensification for Rectal Cancer

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Pathologic complete response rate
Phase:
Phase 2
Details
Lead Sponsor:
CCTU
Treatments:
Capecitabine